Technical Analysis for IKNA - Ikena Oncology, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
20 DMA Support | Bullish | -4.46% | |
Crossed Above 50 DMA | Bullish | -4.46% | |
MACD Bullish Centerline Cross | Bullish | -4.46% | |
Pocket Pivot | Bullish Swing Setup | -4.46% | |
Up 3 Days in a Row | Strength | -4.46% | |
Crossed Above 20 DMA | Bullish | 2.74% | |
Spinning Top | Other | 6.38% | |
NR7 | Range Contraction | 6.38% |
Alert | Time |
---|---|
Possible Inside Day | about 13 hours ago |
60 Minute Opening Range Breakdown | about 14 hours ago |
Fell Below 50 DMA | about 14 hours ago |
Fell Below 10 DMA | about 14 hours ago |
10 DMA Support | about 15 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/12/2024
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.6399 |
52 Week Low | 1.02 |
Average Volume | 419,931 |
200-Day Moving Average | 3.55 |
50-Day Moving Average | 1.50 |
20-Day Moving Average | 1.47 |
10-Day Moving Average | 1.50 |
Average True Range | 0.12 |
RSI (14) | 51.22 |
ADX | 13.63 |
+DI | 24.48 |
-DI | 17.62 |
Chandelier Exit (Long, 3 ATRs) | 1.28 |
Chandelier Exit (Short, 3 ATRs) | 1.64 |
Upper Bollinger Bands | 1.63 |
Lower Bollinger Band | 1.30 |
Percent B (%b) | 0.61 |
BandWidth | 22.18 |
MACD Line | 0.00 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0093 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.64 | ||||
Resistance 3 (R3) | 1.65 | 1.61 | 1.61 | ||
Resistance 2 (R2) | 1.61 | 1.58 | 1.61 | 1.60 | |
Resistance 1 (R1) | 1.56 | 1.56 | 1.54 | 1.55 | 1.60 |
Pivot Point | 1.52 | 1.52 | 1.52 | 1.52 | 1.52 |
Support 1 (S1) | 1.47 | 1.49 | 1.45 | 1.46 | 1.40 |
Support 2 (S2) | 1.43 | 1.47 | 1.43 | 1.40 | |
Support 3 (S3) | 1.38 | 1.43 | 1.39 | ||
Support 4 (S4) | 1.37 |